The Association Between BRAF (V600E) Mutation and Pathological Features in PTC

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2014 Jan 7

PMID 24389984

Citations 25

Authors

Xin Liu

Kangkang Yan

Xuejun Lin

Longyu Zhao

Wenxiu An

Chunpeng Wang

Xiaodong Liu

Affiliations

Soon will be listed here.

Abstract

The BRAF (V600E) mutation is a common genetic alteration in papillary thyroid carcinoma (PTC) and is associated with some pathological features. The association has been widely reported, but results were inconclusive. In this study a meta-analysis was done to explore the association between BRAF(V600E) mutation and pathological features in papillary thyroid carcinoma. Medline, PubMed and Web of Science were searched. A total of 69 studies that included 14,170 PTC patients were identified. The outcomes were from 2004 to October 2013. STATA12.0 software package was used to analyze the data. The result was assessed based on pooled odds ratios (ORs) with 95 % confidence intervals (CIs). The results showed that the BRAF (V600E) mutation was associated with extra-thyroidal extension (OR = 2.09, 95 % CI = 1.69-2.58), advanced TNM stage (OR = 1.90, 95 % CI = 1.62-2.22), lymph node metastasis (OR = 1.68, 95 % CI = 1.41-2.01), multifocality (OR = 1.22, 95 % CI = 1.06-1.40), and recurrence (OR = 2.50, 95 % CI = 1.73-3.59). The meta-analysis suggested the potential roles of BRAF (V600E) mutation in pathological features. BRAF (V600E) might provide prognostic and diagnostic information for papillary thyroid carcinoma.

Citing Articles

Relationship of Recurrence Rate with some Characteristics in Patients with Thyroid Carcinoma.

Tri B, Chi B, Hiep B, Trung N, Minh T, Dung N Indian J Endocrinol Metab. 2024; 27(6):544-551.

PMID: 38371183 PMC: 10871007. DOI: 10.4103/ijem.ijem_134_23.

BRAF Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk.

Park J, An S, Kim K, Bae J, Kim J Cancers (Basel). 2023; 15(22).

PMID: 38001654 PMC: 10670702. DOI: 10.3390/cancers15225395.

Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma.

Bui Dang Minh T, Nghiem Duc T, Phan Nguyen Thanh V, Le T, Duc Tong M, Hoang Nguyen T Clin Med Insights Oncol. 2023; 17:11795549231203503.

PMID: 37905233 PMC: 10613351. DOI: 10.1177/11795549231203503.

Impact of V600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population.

Nechifor-Boila A, Zahan A, Banescu C, Moldovan V, Piciu D, Voidazan S Cancers (Basel). 2023; 15(16).

PMID: 37627081 PMC: 10452493. DOI: 10.3390/cancers15164053.

Germline mutations of B-Raf proto-oncogene and pathological implications in prostate cancer: observational study.

Tiabi I, Ennaji Y, Abumsimir B, Laraqui A, Ennibi K, Mrabti M Ann Med Surg (Lond). 2023; 85(6):2628-2634.

PMID: 37363492 PMC: 10289590. DOI: 10.1097/MS9.0000000000000685.

References

Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M . BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008; 15(1):191-205. DOI: 10.1677/ERC-07-0212. View

ONeill C, Bullock M, Chou A, Sidhu S, Delbridge L, Robinson B . BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010; 148(6):1139-45. DOI: 10.1016/j.surg.2010.09.005. View

Nam J, Jung C, Song B, Lim D, Chae B, Lee N . Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?. Am J Surg. 2011; 203(4):436-41. DOI: 10.1016/j.amjsurg.2011.02.013. View

Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G . BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer. 2011; 18(6):669-85. DOI: 10.1530/ERC-11-0076. View

Cradic K, Milosevic D, Rosenberg A, Erickson L, McIver B, Grebe S . Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab. 2009; 94(12):5001-9. DOI: 10.1210/jc.2009-1349. View

Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L . BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004; 61(2):239-43. DOI: 10.1111/j.1365-2265.2004.02089.x. View

Kim S, Hwang T, Yoo Y, Han H, Kim D, Song K . Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 2011; 96(3):658-64. DOI: 10.1210/jc.2010-1082. View

Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z . Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer. 2008; 113(2):247-55. DOI: 10.1002/cncr.23548. View

Lee J, Huang S, Lee M, Lee S, Ryu M, Kim S . Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. Eur J Endocrinol. 2012; 167(1):93-101. DOI: 10.1530/EJE-12-0010. View

10.

Jeong D, Jeong Y, Lee S, Lee H, Lee W, Kim H . Detection of BRAF(V600E) Mutations in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-Time PCR: A Comparison with Direct Sequencing. Korean J Pathol. 2012; 46(1):61-7. PMC: 3479705. DOI: 10.4132/KoreanJPathol.2012.46.1.61. View

11.

Kim S, Lee K, Myong J, Park J, Jeon Y, Min H . BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2011; 36(2):310-7. DOI: 10.1007/s00268-011-1383-1. View

12.

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A . Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006; 13(2):455-64. DOI: 10.1677/erc.1.01086. View

13.

Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A . In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol (Oxf). 2012; 77(5):780-6. DOI: 10.1111/j.1365-2265.2012.04465.x. View

14.

Kang S, Ahn S, Lee S, Jeong J, Sung J, Oh Y . Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas. Diagn Pathol. 2013; 8:121. PMC: 3751688. DOI: 10.1186/1746-1596-8-121. View

15.

Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas M, Nistal M, Santisteban P . The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006; 13(1):257-69. DOI: 10.1677/erc.1.01119. View

16.

Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P . Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009; 94(5):1612-7. DOI: 10.1210/jc.2008-2390. View

17.

Wang W, Zhao W, Wang H, Teng X, Wang H, Chen X . Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol. 2011; 19(1):31-6. DOI: 10.1245/s10434-011-2096-2. View

18.

Kurtulmus N, Duren M, Ince U, Yakicier M, Peker O, Aydin O . BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine. 2012; 42(2):404-10. DOI: 10.1007/s12020-012-9651-x. View

19.

Jo Y, Li S, Song J, Kwon K, Lee J, Rha S . Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006; 91(9):3667-70. DOI: 10.1210/jc.2005-2836. View

20.

Ahn D, Park J, Sohn J, Kim J, Park S, Seo A . BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx. 2011; 39(2):198-203. DOI: 10.1016/j.anl.2011.07.011. View